Guidewire to Present at Goldman Sachs Communacopia + Technology Conference
Get Alerts GWRE Hot Sheet
Join SI Premium – FREE
SAN MATEO, Calif.--(BUSINESS WIRE)-- Guidewire (NYSE: GWRE) announced that management is scheduled to present at the Goldman Sachs Communacopia + Technology Conference. The Guidewire presentation is scheduled for Monday, September 9, 2024 at 1:45 p.m. ET (10:45 a.m. PT) in New York.
A live webcast, as well as a replay, of the presentation will be available under the "Webcasts and Presentations" section on the Company's investor relations website at https://ir.guidewire.com/.
About Guidewire Software
Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 42 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence (AI), Guidewire defines cloud platform excellence for P&C insurers.
We are proud of our unparalleled implementation record, with 1,600+ successful projects supported by the industry’s largest R&D team and SI partner ecosystem. Our marketplace represents the largest solution partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation.
For more information, please visit http://www.guidewire.com/ and follow us on X (formerly known as Twitter) and LinkedIn.
NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.
GWRE-F
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903098907/en/
Investor Contact:
Alex Hughes
Guidewire
+1 (650) 356-4921
[email protected]
Media Contact:
Melissa Cobb
Guidewire
+1 (650) 464-1177
[email protected]
Source: Guidewire Software, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
- Two Giving Programs Award $600 and Free AC to Valley Residents
- Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged P
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Goldman Sachs, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share